The Efficacy and Safety of Alectinib in Clinical Practice ; Comparision to Crizotinib, in A Multicenter Retrospective Study.
Not Applicable
- Conditions
- ALK rearranged non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000036255
- Lead Sponsor
- Respiratory Centor, Matsusaka Municipal Hospital
- Brief Summary
Sixty-one patients were enrolled. Forty-six patients were treated with ALK inhibitors (31 with crizotinib, 28 with alectinib, and 13 with both ALK inhibitors). The response rate was 66.7% for the crizotinib-treated group and 80.8% for the alectinib-treated group. Among all patients, TTF and PFS were significantly prolonged in the alectinib-treated group compared with in the crizotinib-treated group. OS was significantly longer in the alectinib-treated group than in the crizotinib-treated group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 61
Inclusion Criteria
Not provided
Exclusion Criteria
Nothing
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to treatment failure
- Secondary Outcome Measures
Name Time Method Progression-free survival Overall survival